Max Masucci
Stock Analyst at TD Cowen
(0.21)
# 4,270
Out of 4,944 analysts
22
Total ratings
16.67%
Success rate
-30.77%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $34.54 | +108.45% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $25.68 | -2.65% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $58.57 | -9.51% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $68.98 | +37.72% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $4.79 | +275.78% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $0.38 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.84 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.72 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $1.38 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.18 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.91 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.88 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $101.11 | +364.84% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $9.71 | +157.47% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $44.91 | +222.87% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $34.54
Upside: +108.45%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $25.68
Upside: -2.65%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $58.57
Upside: -9.51%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $68.98
Upside: +37.72%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $4.79
Upside: +275.78%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $0.38
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.84
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.72
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.38
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.18
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.91
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.88
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $101.11
Upside: +364.84%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $9.71
Upside: +157.47%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $44.91
Upside: +222.87%